[illegible]

[illegible]-[illegible]

[illegible]?

[illegible]

[illegible] · [illegible] · [illegible] · M30s / [illegible] / [illegible] · [illegible]-[illegible]

[illegible]: [illegible] ([illegible]) [illegible]-[illegible] | [illegible].

⚠ [illegible] — [illegible] | [illegible]: 112 '[illegible] findahelpline.com '[illegible]

[illegible]

[illegible] XYLAZINE [illegible], [illegible] Naloxone [illegible]-[illegible] 112 '[illegible]

MAT ([illegible]/[illegible]) "[illegible]" [illegible] '[illegible]

[illegible].

[illegible], [illegible]: '2013–[illegible]: [illegible] — [illegible]-[illegible] (prescription opioids) [illegible], [illegible] (heroin) [illegible], [illegible]; [illegible] (morphine) [illegible] 50-100 [illegible]; [illegible] (cocaine), [illegible] (MDMA), [illegible] (methamphetamine) [illegible]; [illegible]'

[illegible]—[illegible], [illegible] '[illegible], [illegible]—[illegible]-[illegible]—[illegible], [illegible] 1963 [illegible], [illegible]

[illegible]

[illegible]—2022 [illegible] 110,000 [illegible]—[illegible] 30mg [illegible]

[illegible]: [illegible] 0 [illegible] 112 '[illegible], [illegible] (Naloxone) [illegible], [illegible] 0 [illegible]

[illegible] MAT ([illegible]) [illegible]: [illegible] '[illegible] - [illegible]

מדריך שטח: זיהוי מהיר ותגובה ראשונית לאירועי חשיפה לחומרים מסוכנים בשטח פתוח ובמבנים סגורים, כולל פרוטוקול מיון ראשוני בזירה מרובת נפגעים

שלב 0 — מיון ראשוני: הגנה עצמית

⚠ אזהרה: אין להיכנס לזירה ללא ציוד מגן מתאים אלא אם כן ברור לחלוטין שאין חשיפה לחומרים מסוכנים. כניסה לא מוגנת עלולה להפוך את הנפגע הראשון לנפגע נוסף ולסבך את פעולת כוחות ההצלה כולה.

0.1 — זיהוי מהיר של חומרים מסוכנים ואיתותי אזהרה

זיהוי חזותי — מה לחפש לפני שמתקרבים

סימנים, ריחות, התנהגויות של בעלי חיים ושינויים בצמחייה עשויים להעיד על חשיפה לחומרים מסוכנים—גם כאשר אין נפגעים גלויים לעין. חשוב לזכור שחלק מהחומרים אינם ניתנים לזיהוי בחושים האנושיים, ולכן היעדר סימנים אינו מבטיח בטיחות. יש להתייחס לכל אירוע חשוד כאילו הוא מסוכן עד שהוכח אחרת.

מה רואים	מה זה עשוי להעיד	Response
בועות, קצף או שינוי בצבע המים - במיוחד סביב מקורות מים	חומרים מסוכנים עלולים לגרום לשינויים בצבע המים, בצורת הבועות או בהתנהגות הדגים. אין להסתמך על כך כאינדיקציה יחידה.	שמרו מרחק של 112 מטרים לפחות מהמים. אל תיגעו במים ואל תשתו מהם. אל תכניסו ידיים למים.
ריחות, כאבי עיניים או גרון, בחילה או סחרחורת — 5 אנשים ומעלה באותו מקום ובאותו זמן	חשיפה לחומרים מסוכנים עלולה להשפיע על מספר אנשים בו-זמנית. אין להסתמך על חוש הריח כמנגנון הגנה.	התרחקו מהאזור (לפחות 0.2)ק. אל תכנסו לחללים סגורים. אל תנסו לטפל בנפגעים. דווחו מיד על 112 'ל. אל תחזרו לאזור עד שיינתן אישור.ל
התנהגות חריגה בבעלי חיים (במיוחד)ק.	חומרים מסוכנים עלולים לגרום לשינויים בגודל האישונים (pupils) בהתנהגות או בתגובות של בעלי חיים. אין להסתמך על בעלי חיים כמנגנון אזהרה יחיד.	אל תתקרבו לבעלי חיים חולים או מתים, במיוחד אלה שמראים סימנים חריגים (קשיי נשימה, רוק מוגזם) או אלה שנמצאים: התרחקו מבעלי חיים חולים (במיוחד) ואל תאכילו אותם. אל תיגעו בבעלי חיים מתים (Naloxone) ודווחו.

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible], [illegible] [illegible] ([illegible])[illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]

	[illegible] [illegible] 2-3 [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] 4mg [illegible] [illegible] [illegible] 2-4 [illegible] [illegible] [illegible] [illegible] [illegible]
KLOXXADO [illegible] [illegible] (8mg - [illegible] [illegible])[illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

5. [illegible] Naloxone [illegible]
6. [illegible]
7. [illegible]
8. [illegible]
9. [illegible]

0.3 — [illegible]

⚠ **XYLAZINE ('TRANQ')** [illegible] **Naloxone, XYLAZINE** [illegible] **112** [illegible] **— XYLAZINE** [illegible]

Xylazine ([illegible] Rompun) [illegible] Naloxone [illegible]

[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]: [illegible]	[illegible]	[illegible]

[illegible]	[illegible]	[illegible]
[illegible] (FDA) [illegible]	[illegible]	112[illegible] [illegible]

0.4 — [illegible]: [illegible] 30, [illegible]

⚠ [illegible]

[illegible] [illegible] M30 [illegible] 30mg [illegible] ('M' [illegible] '30'), [illegible] 'Percocet' [illegible] [illegible] [illegible]

[illegible]), [illegible], [illegible]

0. 5 — [illegible]?

- [illegible]: [illegible] '[illegible]
- [illegible]: [illegible] Naloxone [illegible], [illegible]
- NEXT Distro (nextdistro.org): [illegible] Naloxone [illegible]
- SAMHSA National Helpline (1-800-662-4357): can direct to local naloxone distribution programs
- [illegible]: [illegible] Naloxone [illegible]
- NEXT [illegible] NEXT [illegible]: [illegible]

□□□□□□□ 1 — □□□□□□□□ □□ □□□□□□□ □□□□□ □□□□ □□ □□□□□

□□ □□□□□□□□□□ — □□ □□□□ □□□□□□□□□□□ □□□□□□ □□□□-□□□□□□□ □□□□□□□□ — □□□□□□□□□□ □□□□□ □□ □□□□□□□□□□

□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□ □□—□□ □□□□□□ □□ □□□□□ □□□□ □□□□□ □□□□□, □□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□—□□□ □□ □□□□-□□□□□□□ □□□□□□□□ (MOR) '□□ □□□□ □□□□□ □□□□□□□□ □□□□ □□ □□□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□ □□ □□□□□□□□□□ □□□□□ □□□□ □□□□□□ □□□□ □□: '□□□□□□□□□ □□□□□□ □□□□ → HPA □□□□□□ □□□□□□□ □□□□□□ → □□□□□□□ □□□□ □□□□□□□ □□□□□□ □□ □□□□□ □□□□□□□□□ □□—□□□□□□□ □□□□ □□□□□□□□□ □□□□ '□□□□ □□□□ □□□□□□□□ □□□□□ □□□□ □□□□□□'

□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□□ □□□□□□□□□ □□ □□ □□□□□□□□ □□□□□□ □□□□-□□□□□□ □□□□□□□□□□ □□ □□□□□□□□□□ □□ □□□□□□□□ □□□□□□ □□□□□□□□ '□□ □□ □□□□□ □□ - □□□□ □□□□□ □□□□□□□□□□ □□□□□ □□□□□ □□□□□□ □□□□ □□ □□□□□□□□□ □□□□ □□□□□□ □□ □□□□□□ □□ □□ □□□□□□□ □□ □□□□□□□□ □□□□□□□□ □□□□ □□□□ □□□□□□ □□ □□□□ □□□□□□ □□, □□□□□□ □□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□□ □□□□□□

1.1 — □□□□-□□□□□□ □□□□□□□□ □□□□□□: □□□□ □□□□□ □□□□ □□□□□ □□□□ □□□□ □□?

MOR □□□□□□ □□ □□□□ '□□ □□ □□□□□ □□□□	□□□□□□ □□□□□□□□□ □□ □□□□□□ □□□□□□□□□ □□□□□□	□□ □□□□□□□ □□ □□ □□□□□□□ □□ □□ □□□□ □□□□
□□□□ □□□□ □□□□□□□□□ □□□□ □□ □□□□□□□□□— □□□□□ □□ □□□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□	□□□□□□□□ □□ □□□□□ MOR □□□□□□□□ (MOR agonism) □□□□□ □□□□□, □□□□□□ □□□□ □□□□□ □□□□□□ □□—□□ □□□□□ □□ □□□□ □□□□ □□ □□□□□□ □□□□□□□ (opioid) □□□□□□□□ □□□□ □□□□ □□□□ □□ □□ □□ □□ □□□□□□□□ □□ □□□□□□ □□□□□□□ □□□□□□□□□□□□ (surgical anesthesia) □□□□□ □□□□□ □□□□□□ □□□□ □□□□ □□□□□ □□□□□□□□□□□ (mechanism) □□ □□□□□□ □□□□□□□ □□□□ '□□ □□□□□□□□ □□□□□□□□ □□, □□ □□ □□□□□□ □□□□□ □□ □□□□□□□ □□ □□ □□ □□□□□□ □□□□ □□□□ □□□□□ □□, □□□□□□□□□□□□□□□□ (pharmacologically) □□□□□□ □□□□□□□□ □□□□	□□□□□□□□□ □□□□□□, □□ □□ □□□□ □□□□ □□□□□□□□□ □□ □□□□ □□, □□ □□□□□ □□□□□□□ □ □□ □□□□ MOR □□□□□□□□□□ □□ □□□□ □□□□ □□ □□□□□ □□ □□ □□□□□□□ □□□□ □□□□ □□□□□ □□□□ □□□□ □□□□ □□ □□□□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□ □□ □□□□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□, □□ □□□□ □□□□□□□ □□□□□□ □□□□-□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□ □□□□□□□ □□□□
□□□□□□□□□ □□□□□ □□ □□□□□□□□—□□□□□□□□□ □□□□, □□ □□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□□□ □□□□□ □□□□	□□□□□□□□ □□ MOR □□□□□□□□□ □□□□□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□ □□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□□□ □□□□□□□ □□ — □□ □□□□ □□□□□□□□□ □□□□□ □□ □□□□-□□□□ □□□□□□□□□ □□□□□ □□ □□□□□□ □□□□ □□ □□□□□□□ □□ □□ □□□□□□□□ □□ □□□□□□ □□□□□□ □□□□□□□□□ □□□□□ □□□□ □□□□ □□□□ □□ □□□□□, □□□□□ □□□□□□□, □□□□□□□□,	□□□□□□□□ □□□□□□ □□□□□□□□□ □□□□ □□□□□ □□□□□□□□□ □□□□ □□□□□□□□ □□□□ □□□ □□□□ □□□□ □□□□□ □□□□□□□ □□ □□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□□□ □□—□□□□□□ □□ □□□□□□ □□ □□□□□, □□□□□ □□ □□□□□ □□□□ □□□□□□□□, □□□□□□□□ □□ □□□□□□□, □□□□ □□□□□□□□□ □□□□□□□□

	[illegible] [illegible] [illegible]

[illegible]	1x ([illegible])	[illegible] [illegible] [illegible]

- [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]

	[illegible] [illegible] [illegible]

□□□□ □□□: □□ □□□□□□□ □□□□□ □□□□□□□ □□ □□□□□ □□ □□ □□□ □□□□□ □□□□□□ □□□□ □□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□□□ □□□ □□□ □□□□ □□□ □□□□□□□□ □□, □□□ □□□□□ □□□□ □□□□ □□□ □□□□□ □□□ □□□ □□□□

□□ □□□ □□□□, □□□□ □□□□□□ □□□□□□□ □□□□□□□ □□□□ □□□ □□□□□□, □□□□□□ "□□□□□□□ □□□□□□□□□" □□□□ □□□□□ □□□ □□ □□□□□□□ □□□□□□ □□□□ □□ □□□ □□□ □□ □□□□□ □□□ □□□ □□□□□□□□ □□□ □□□□□□□□ □□□ □□ □□□□□□□ □□□ □□□□ □□□□ □□□ □□ □□□□ □□□

* □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□ □□□□□ **(parents)** □□□ □□□□□□□□ **(inherited)** □□□□ □□ □□□□□ □□ □□□ □□□□□□□ □□□□□ □□□
* □□ □□□ □□□□□□ □□□□ □□ □□ □□□□□ □□□ □□□□□□□□ □□□□ □□, □□□□□ □□ □□□□□□ □□□□, □□□□□ □□ □□□ □□□ □□□ □□□□□□□□ □□ □□□□□□ □□□□□□□□□
* □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□ □□□□ □□ □□□ □□□ □□ □□□□□ □□□□ □□□□□□□□□ □□□□□□□ □□□□□□ □□ □□□□ □□, □□ □□ □□□□□□ □□□□ □□ □□□□□□ □□□ □□□□□□□□ □□□ □□ □□□□□□□ □□ □□□□ □□□□□ □□□□ □□□□□□
* □□□□ □□□□ □□□□, □□□□□ □□ □□□□□□ □□□□, □□□□□□ □□□□□□□ □□□ □□□□□□ □□□□□□□□□, □□ □□□□□□ □□□□ '□□ □□□ □□ □□□□ □□□

□□□□ □□□□□ □□□□ □□□□□□□ □□□□□□□□□ □□□□ □□□ □□□□□ □□□□□□□ □□, □□□ □□□□□ □□□□ □□□□ □□□ □□□□□

[illegible]

[illegible] '[illegible] [illegible], CYP2D6 [illegible] '[illegible] OPRM1 [illegible]-[illegible] [illegible], [illegible], [illegible] MAT ([illegible]-[illegible]) [illegible]

[illegible]

[illegible]	[illegible]	[illegible]	[illegible]
OPRM1	[illegible]-[illegible] — [illegible] '[illegible], [illegible], [illegible]	A118G (rs1799971) — A/A: [illegible], A/G: [illegible], G/G: [illegible]	[illegible] G [illegible]-[illegible]— [illegible] '[illegible] ([illegible], [illegible], [illegible]) [illegible]: (1) [illegible]; (2) [illegible] MAT ([illegible]-[illegible]) [illegible] G [illegible]— [illegible]: G/G [illegible]— [illegible]... [illegible] श[illegible], [illegible]
CYP3A4	[illegible] — [illegible]	[illegible] (Inducers) [illegible] (Inhibitors); [illegible]	[illegible] '[illegible] CYP2D6 [illegible], [illegible] - [illegible], CYP3A4 [illegible]

	[illegible]	[illegible]	[illegible] CYP3A4 [illegible] ([illegible], [illegible], [illegible] HIV [illegible]) [illegible] CYP3A4 [illegible] ([illegible], [illegible], [illegible]) [illegible] '[illegible] ([illegible]) [illegible] HIV [illegible] - [illegible] ART [illegible] CYP3A4 [illegible], [illegible]
CYP2D6	[illegible]	[illegible] (*4/*4), [illegible], [illegible] (*1x2 [illegible])[illegible]	[illegible] '[illegible] CYP2D6 [illegible]: "[illegible]" [illegible], CYP2D6 [illegible]-[illegible], [illegible]-[illegible] CYP2D6: [illegible] ([illegible], FDA [illegible])[illegible] CYP2D6: [illegible] ([illegible])[illegible], [illegible]
COMT	[illegible]; [illegible] '[illegible]	Val158Met (rs4680)	COMT, [illegible]: (1) [illegible] — Met/Met ([illegible], [illegible] COMT) [illegible], [illegible] (opioids) [illegible]; (2) [illegible] — [illegible], [illegible], [illegible] COMT-[illegible] (COMT-mediated) [illegible] (stimulant) [illegible] "[illegible]" [illegible]: [illegible], [illegible] (opioid receptor) [illegible]-[illegible]
MTHFR	[illegible] - [illegible],	C677T (rs1801133),	MTHFR [illegible]

	[illegible]	A1298C (rs1801131)	[illegible] — [illegible] MTHFR [illegible], [illegible] 5-MTHF [illegible] '[illegible]
SLC6A4 / 5-HTTLPR	[illegible] — [illegible].	[illegible]/[illegible]	SLC6A4 [illegible] "[illegible]/[illegible]" [illegible] MOR [illegible] '[illegible] [illegible]—[illegible] GABA [illegible], [illegible] "[illegible]/[illegible]" SLC6A4 [illegible] '[illegible] ([illegible]) [illegible] '[illegible] ([illegible] 4)[illegible]
GABRA2	GABA-A [illegible] — [illegible]	rs279858 [illegible]	[illegible] - [illegible] GABRA2 [illegible]: GABRA2 [illegible] GABAergic [illegible] '[illegible]

[illegible]

- [illegible]? [illegible], [illegible]? → [illegible] '[illegible] OPRM1 A/G [illegible] G/G [illegible], [illegible]—[illegible]

- □□ □□□□□ □□□□ □□□ '□□ □□□□□ □□ □□□□, □□□□ □□□ □□ □□□□□□□□ □□ □□□□□ □□□□? → COMT Met/Met (□□□□ □□□□ □□□ □□□□□□□) + OPRM1 G □□□□ (□□□□ □□ □□□□□□ □□□ □□□) + □□□□□□□ □□□ '□□ MTHFR (□□□□ □□□ □□□□□□□□ □□□□□□□□ □□□□□□□□)□ □□□□□□□ □□□ □□ □□□□□□□ □□□□ □□□□□□ □□□□□ □□ □□□□□ □□, □□ □□□ □□□□□ □□□□ □□□
- □□ □□□ □□□□□□ □□ □□□□□□□□ '□□ □□□□ □□□ □□□ □□□ □□□□—□□□ □□□□ □□□.□□.□□. □□□□□□, □□□□□□□□ □□□ □□□ □□□□□□□□□□□□□? → CYP3A4 □□□□-□□□□ □□□□□ □□□□□□□ □□□□ CYP3A4 □□□□□□□□□ (inhibitors) □□□ □□□□□□□□ (inducers) □□□□ □□□□—□□□□ □□□□□□□□ □□ □□□□□ □□ □□□□□□□ '□□ □□□ □□ □□□□ □□ □□□ □□ □□□□ □□□□□□ □□□□ □□□□ □□□□□□□□ □□ □□□□ □□ □□□□ □□□
- □□ □□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□ □□□ □□□□□□□□□□□□□□□ □□ □□□□□ □□□□ □□? → □□□□□□□ GABRA2 □□□ □□□□ □□□□ □□□□□□□□□□ □□□□□□□□ □□□ □□□ □□□□□/□□□□□□□ □□□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□□ □□□ □□ □□□□□□□ □□□ □□□ □□□□□□ □□□□□□ □□□□□□□ □□□□□□ □□□
- □□ □□□□□ □□□ □□□□□□□□ □□□□, □□□□□ □□□□ □□ □□□-□□□ □□□□ □□□□ □□? → SLC6A4 □□□□□/□□□□□ + COMT □□□□/□□□□ □□□ □□□□□□□□□ □□□□□ □□ □□□□ □□□ □□□□□ □□□□□□ □□□□□ □□□

□□□□ 3 — □□□□ □□□ □□□□□□ □□□□ □□□□: □□ □□□□ □□ □□□ □□□□□□□ □□□

□□ □□□□□□□□□□ — **MAT (□□□□□□□□□□-□□□□□□□ □□□□□□□□□□) "□□□ □□□□□□ □□□□"** □□□□ □□□ □□□□□□□□□□ □□ □□□□□□ □□□□ □□□□□□ □□: □□ □□□□ □□□

□□ □□□□□□□ □□ □□□□ □□□□□□ □□: "□□□ □□□□□ □□ □□□□□ □□□ □□□□ □□□□□ □□ □□□□ □□□□□□□□□ □□□□□□ □□ □□□□ □□□□ □□ □□□□ □□□□□ □□, □□ □□□ '□□□□□□□' □□—□□□□□□, □□□□□□, □□□ □□□□-□□□□□ □□□ □□□□□ □□ □□□□□□ □□□□□□ □□ □□□□ □□□ □□□□□□□ □□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□, □□ □□□□ □□ □□□□ □□□ □□□□□□□ □□ □□□□□ □□□ □□ '□□□□□□□' □□ □□□□□ □□□ □□□□ □□□ □□□ □□□□□ □□, □□ □□□□ □□□□ □□□□□ □□□□ □□□□ □□ □□□□ □□□□□□"

□□□□□ □□ □□□□□ □□ □□□□□ □□, □□□ □□□□ □□□□□□□ □□ □□□□ □□□□, □□ □□□□□ □□□ □□□□□□□□□ □□□□ □□□ □□□ □□□□ □□□□□ □□: □□□□□□□ □□□□□□□ □□□□, □□ "□□□□ □□□□□" □□ □□□□□□ □□□ □□□□ □□□□□ □□□□□ □□ □□ □□ □□□ □□ □□□ □□□□ □□ □□□□ □□□□ □□□□ □□□□□□ □□□ □□□□□□□□□□□□□ □□□ □□□□□□ □□□□□ □□ □□□□□□□□ □□□ □□ □□□□ □□□ 50-70% □□□ □□□□□□□ □□□ □□□□□ □□□ MAT (□□□ □□□ □□ □□□□□□) '□□ □□□□□□ □□, □□ □□□□ □□□□ □□□□ □□□□ □□□ □□□□□□ □□, □□□□ □□□□□□ □□□ □□□□□□ □□□□□ □□, □□□ '□□ □□□□ □□□□□ □□ □□□ □□□□ □□□ □□□□□ □□□ MAT □□□ □□□ □□□□□ □□ □□□ □□□□□ □□□□□ □□□□□□ □□□□ □□ □□□□,□□ □□□□ □□□□□□ □□□□ □□□ □□□□ □□□□.

□□□□□□ □□□□ □□□□-□□□□□ □□□□ (MAT) □□□ □□□□□□ □□ □□□□-□□□ □□□ □□□□ □□□□ □□□□□□ □□ □□□□□ □□□ □□□□□□ □□□□ □□ □□□□ □□□ '□□ □□□□ □□□□ □□□□□ □□□□ □□□□□ □□—□□ □□ □□□□□□□ □□□□□ □□ □□□ '□□ □□ □□□□ □□ □□□□ □□□□□ □□ □□□ □□□□□□ □□□

3.1 — □□□□ FDA-□□□□□□□□ MAT (□□□□□□□□□□-□□□□□□□ □□□□□□□□□) □□□□□□

□□□□	□□□□□□□□□□	□□□□□□□□	□□□□ □□□ □□□□□□
□□□□□□□□□□□□□□□□ (□□□□□□□□, □□□□□□□□, □□□□□□□□, □□□□□□□□)	□□□□□□ □□□-□□□□□ □□□□□□□□ □□□□□□□□ — □□ MOR □□□ □□□ □□□□□ □□□□□□ □□□□ □□□□□ □□□□ □□, □□□ □□□ □□□□ □□□ □□□ □□□□ □□ □□□□□ □□□ □□□ □□□□ □□ □□□□ □□, □□ □□ □□□□ □□□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□□□□□ □□□□ □□□□□□□ □□□ □□□□□ □□□□ □□ □□□ □□ □□□□ □□□□□□□□ □□□ □□□□□	□□□□□□□□□ □□□□ □□□ □□□□ (□□□□□□□□): □□□□□□□□□ □□□□□□□□: □□□□□□□□□ □□□□ □□ □□□□□□ □□□□□□□□□□ □□□□□□□□□: 6 □□□□□□□□ □□□ □□□□ □□□□ □□□□□□□□□	□□□□□ □□□□□ □□□□□ □□ □□□□□ □□□□ □□ □□□□□ □□□ □□□□ □□ □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□ □□ (2023 □□□□ DEA X-waiver □□ □□□ □□□□ □□ □□ □□ - □□□ □□ DEA-□□□□□□□□□ □□□□□□□□□□ □□□□ □□□□□ □□ □□□□ □□)□ □□ □□□ □□□□ MAT □□□□□□□ □□□ □□ □□□ □□□□□ □□ □□□□□□□ □□□□ □□□ OPRM1 □□ □□□□: □□□□□ □□□□ □□□□□ □□ □□□ □□ □□□□ □□□ CYP3A4 □□□□□□□□□□□ □

			relevant□□□□ □□.
□□□□□□□	□□□□ □□□-□□□□□ □□□□□□□□ — □□ MOR □□□ □□□□ □□□□□□ □□□□□□□ □□□□ □□, □□□ □□□□ □□□ □□ □□□□□□ □□□□□ □□□□ □□□ □□□ □□□□ □□□ □□□□□ □□, □□ □□ □□□□□□□ □□□ □□□□□□ □□□□□ □□□□□□□□	□□□□□□□ □□□□ □□□□□ □□□ □□□□ □□□□ □□ □□ □□□□□ □□□□□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□□□□ (OTPs) □□□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□ □□ □□□□□□□□ □□□□□ □□□□□ □□□□□ □□ □□□□□ □□ □□□□ □□□□□ □□ □□□□— □□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□ □□□□	□□□□□ □□□□□ □□ □□□□□ □□ □□ □□□ □□ □□□□□□□□ □□□□, □□□ □□□□ □□□□□□□ □□ □□□□□ □□□ □□□□□□ □□ □□□□□ □□□□ □□□□□□□ □□ □□ □□ □□□ □□□□ □□ □□□ □□□□□ □□□ QTc □□ □□□□□ □□ □□□□ - □□□□ □□□ □□□□□□ □□□ □□□□□ □.□□.□□. □□□□□□ □□□□□□ □□ □□□□□□ □□□□□□□□□□□□□□□ □□ □□□□□□□ OTP (□□□□□□□□ □□□□□□□□□ □□□□□□□□) □□□□□□□□ □□□□□ □□□□□ □□□ □□ □□□□□ □□□□□□ □□□ □□□□□□□ □□□□ □□□□□ □□□ □□□ □□ □□□□ □□□□ □□ □□□□, □□ □□□□□□□□□□□□□□ □□ □□□ □□□
□□□□□□□□ (Vivitrol) □□□ □□□□ □□□□ □□□ □□□□ □□□□ □□□□□□□□□□□ □□□	□□□□ □□□-□□□□□ □□□□□□□ □□□□□□□□□□ — □□ □□□□ □□□□□ □□ □□□□□□□□ □□□ □□□□ □□□□□□ □□□ □□□□□ □□ MOR (□□□ □□□□□ □□□□□□□) □□□ □□□□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□□□□□□	□□□□□□□ □□□□□□□□□□□ (□□□□ □□□□) □□□□□ □□□□ □□□□□□□ □□□ □□□ □□□□□□, □□□□ □□□□□□ □□□ □□□□ □□□□□□ □□□□□□ □□□□□ □□ — □□□□□□□□□□ □□ □□□□ □□□□□ □□ □□□ □□□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□ □□□	□□□□□□□□□ □□□□ □□□ □□□ □□□□ □□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□ OPRM1 □□ □□□□: □□ □□□□□□□□□□ □□ □□□ □□ □□□ □□ □□□□□□□□□ □□□□□□□□ □□□ □□□□ □□□□□□□ □□□ □□□ □□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□ □□□□ □□□□ □□□□□□ □□ (□□□□□□□□□□ 7-10 □□□), □□ □□□□ □□□□□□ □□□□ □□□□ □□□□□ □□□ □□ □□□□ □□ □□□ □□□□ □□□□ □□□□□□□ □□□□□□□ □□□ □□□□□ □□□ □□□□ □□ □□□□□ □□□□ □□□□□ □□□ □□□□ □□□□ □□□□ □□□□ □□ □□□□ □□□□ □□□ □□□□ □□□□ □□□□ □□□ □□□□□□ □□□□□

3.2 — □□□□□□□□ □□ □□□□□□□ □□□□□□□ □□ □□□ □□□□□□ □□ □□□□□ (MAT).

⚠ □□□□□□□ □□ □□□ □□□□□□□ □□□□□□□ □□□□□□ □□ □□□□ □□ □□ □□□□□□□□□□□□□ □□□□□□□, □□□□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□ □□□□ □□□□ □□□□□ □□□□ □□□□□ □□, □□□ □□□□ □□□□□□□ □□ □□□□ □□ □□□□ □□□ □□□□□□□ □□ □□□□ □□□□ □□□□ □□□□□ □□□ □□□□□□ □□□□

[illegible], [illegible] MAT ([illegible]) [illegible]:

- [illegible]: [illegible], [illegible], [illegible]—[illegible], [illegible], [illegible]-[illegible] '[illegible]' [illegible] ([illegible]) [illegible]—[illegible]
- [illegible] '[illegible]: [illegible]-[illegible] '[illegible], [illegible], [illegible]-[illegible], [illegible] '[illegible]
- CYP3A4 [illegible]: [illegible] CYP3A4 [illegible] CYP3A4 [illegible] MAT [illegible]
- MAT [illegible]: [illegible] MAT ([illegible]-[illegible]) [illegible] ([illegible]) [illegible], [illegible] MAT [illegible], [illegible] ([illegible]) [illegible] ([illegible]) [illegible] '[illegible]' [illegible], [illegible] ([illegible]) [illegible]

3.3 — [illegible] (MAT) [illegible]

- SAMHSA Treatment Locator (findtreatment.gov or 1-800-662-4357): finds buprenorphine prescribers and methadone clinics by location
- [illegible] (2023 [illegible]): [illegible] DEA-[illegible], [illegible], [illegible] X-[illegible]
- [illegible]: [illegible] (Done Health, Bicycle Health, Ophelia, Monument [illegible]) [illegible] — [illegible]
- [illegible]: [illegible], [illegible] '[illegible]' [illegible]
- [illegible]: [illegible], [illegible]

- [illegible]: [illegible] [illegible] [illegible] [illegible] MAT ([illegible] [illegible] [illegible] [illegible]) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] MAT [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

▯▯▯▯ ▯ — ▯▯▯▯▯ ▯▯▯-▯▯▯▯▯▯▯: ▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯▯▯

▯▯ ▯▯▯▯▯▯▯▯▯▯ — ▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯

▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯ ▯▯: '▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ → ▯▯.▯▯.▯. ▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯ ▯▯ ▯▯▯▯ ▯▯ ▯▯▯▯▯ → ▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯' ▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ — ▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯, MOR ▯▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯, ▯▯▯▯ HPA ▯▯▯▯▯▯ ▯▯▯▯ ▯▯ ▯▯▯▯▯ ▯▯ ▯▯ ▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯ ▯▯▯▯ ▯▯▯▯

▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ MAT (▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯▯▯▯) '▯▯ ▯▯▯▯▯ ▯▯▯▯ MAT ▯▯▯▯▯▯▯ MOR (▯▯▯▯▯▯) ▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯ '▯▯ ▯▯▯▯▯ ▯▯▯▯▯ ▯▯—▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯ MOR ▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ (▯▯▯▯▯) ▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯, ▯▯▯▯▯ ▯▯ MAT ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯

4.1 — ▯▯▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯▯

▯▯▯▯▯▯▯▯▯▯	▯▯▯▯▯	▯▯▯▯▯▯	▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯
5-MTHF (L-▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯)	400–1000 mcg ▯▯▯▯▯▯▯▯▯	▯▯▯▯▯▯ ▯▯▯▯▯▯	▯▯▯▯▯▯▯▯▯ (▯▯▯▯▯-▯▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯) ▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯, ▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯ MTHFR ▯▯▯▯▯▯▯▯▯▯▯▯▯ ▯▯ 5-MTHF ▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯ ▯▯, ▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯—▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯ '▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯▯ ▯▯▯▯ 5-MTHF ▯▯▯▯▯▯ ▯▯▯▯ '▯▯ ▯▯ ▯▯▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯
▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯ (B12)	1000–2000 mcg ▯▯▯▯▯▯▯▯▯▯▯▯▯	▯▯▯▯▯▯	▯▯▯▯▯▯ B12, ▯▯ ▯▯ ▯▯▯▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯, ▯▯▯▯▯▯ 5-MTHF ▯▯ ▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯ ▯▯▯▯▯ ▯▯▯▯▯▯ ▯▯ ▯▯▯▯▯ B12 ▯▯▯▯ ▯▯▯▯ ▯▯ ▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯▯ ▯▯▯▯ ▯▯▯▯ '▯▯

			[illegible] [illegible] [illegible] [illegible]—[illegible] [illegible]ilibrium [illegible] [illegible] [illegible]

			[illegible]) [illegible] [illegible], [illegible] [illegible] [illegible]

			[illegible] [illegible] [illegible] [illegible] 'לא MOR-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] 5-HTP לא [illegible] [illegible] [illegible] [illegible] לא [illegible] לא [illegible] [illegible] [illegible] לא לא [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible])।	[illegible]—[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] OUD ([illegible] [illegible] [illegible]) [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]	[illegible], [illegible] - [illegible], [illegible]	[illegible]

4.4 — [illegible] (PAWS) [illegible]

[illegible] (opioid withdrawal) [illegible]: 'HPA [illegible] (axis) [illegible] → [illegible]—[illegible] '[illegible]'

- [illegible] ([illegible]-2 [illegible]): [illegible] HPA [illegible] — [illegible] ([illegible], [illegible], [illegible], [illegible], [illegible] '[illegible]) [illegible], [illegible] '[illegible]: [illegible], [illegible]
- [illegible] ([illegible]): [illegible] '[illegible], [illegible] '[illegible]: [illegible]—[illegible]
- NSAIDs [illegible]: [illegible] (withdrawal) [illegible]
- [illegible]: [illegible], [illegible] NMDA [illegible] GABA [illegible] '[illegible]
- [illegible]: [illegible]-[illegible] [illegible]-[illegible] — [illegible], [illegible]
- PAWS ([illegible]-[illegible] [illegible]): [illegible] PAWS 6 [illegible] 18 [illegible], [illegible], [illegible] 4.2 [illegible] 6 [illegible] NAC, DLPA, [illegible] PAWS [illegible] '[illegible] PAWS [illegible]

4. 5 — [illegible]

[illegible]: '60–75 BPM, [illegible] ([illegible], [illegible]-[illegible]), 528 Hz '[illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible]'

- [illegible]: 0.5–1mg [illegible], [illegible] 30–60 [illegible] — HPA [illegible]-[illegible]
- [illegible]: 400 [illegible], [illegible]
- [illegible]: 3-5 [illegible], [illegible] 30 [illegible] ([illegible])[illegible]
- L-Theanine: 200–400mg [illegible]-[illegible]; [illegible]
- 5-HTP: [illegible] 50 [illegible]-[illegible]

MAT ([illegible]) [illegible] '[illegible], [illegible] MAT [illegible]-[illegible], [illegible]

4.6 — [illegible]

[illegible] — [illegible]

- [illegible] (HCV): [illegible] HCV [illegible] HCV [illegible]: [illegible] HCV RNA [illegible]—8 [illegible] 12 [illegible]-[illegible], [illegible] 95% [illegible], [illegible] HCV [illegible] '[illegible]' [illegible]—HCV [illegible]
- HIV: [illegible] HIV [illegible]: [illegible] ART ([illegible]) [illegible] U=U ([illegible] = [illegible]) [illegible] HIV [illegible]: [illegible] ARTs [illegible] CYP3A4 [illegible] - [illegible] '[illegible] HIV [illegible]
- [illegible]: [illegible], [illegible], [illegible]
- [illegible]: [illegible], [illegible]-[illegible], [illegible] '[illegible]
- [illegible]: IV [illegible], [illegible]

□□□ □□□□ □□□□□□□□, □□□ □□□□ □□ □□□□□□ □□□□ □□□□□ '□□ □□□□□□□□□ □□ □□□ □□□□□□ □□ □□□□□□□□□□ □□ □□□□□ □□□□□

4.7 — □□□□□□ □□□□□□ □□□□

□□□□□□□□	□□□□□□□□□ □□□□□□ □□ □□ □□□□ □□□□□□□□□ □□?	□□□□	□□□□
BPC-157	□□□□□ □□□□ □□□□□□□ □□ □□□ □□□□□□ □□□□ □□□□□□□□□□□ MOR □□□□□□ □□□□□ □□ □□□□□; □□□□□ □□ □□□□□ □□□□ □□□ □□□□ □□□□ □□□□□ □□□ □□□□ □□□-□□□□ □□□□□ □□ □□□□□□; □□□□□□□□ □□□ □□□□□□□□ □□ □□□□□ □□□□□□; □□□□□□□ □□□□□ □□ □□□□□□□□□□□□□□ □□□ □□□□□-□□□□□□□□	□□□□□ □□□ □□□, □□□ MAT (□□□□□□□ □□□□□□□ □□□□□□□□□□) □□ □□□ - □□□□□□□□	BPC-157 □□□□□□□ □□□□□□ □□ □□ □□□ □□□□□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□ □□ □□□□ □□□□ □□□□□ □□□□ □□□□□□□□ '□□ □□□□ □□ □□□□□□□ □□□ □□□ □□□□□ □□ □□ BPC-157 □□□□□□ □□□□□□□□ □□ □□□□□□□ □□□ □□□□□□□ □□ □□□ □□□□□□□□□□□□□ □□□□□□ □□□□ □□□ □□□□ □□□ □□□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□□ □□□ □□ □□□□□□ □□□ □□□□ □□ □□□□ □□—□□ □□□□□ □□□□□ □□□ □□□ □□□□
□□□□□□□□	□□□□□ (GABA) □□□ □□□□□□□□□□ □□ □□□□□ □□□□ □□□□□; □□□□ □□□□□ □□□□ □□□□; □□ □□□□□□ □□□□ □□□□□ □□□ □□.□.□□□□□.□□□. (PAWS) □□□□ □□□ □□□□ □□□□ □□□ □□□□□□□ □□, □□ □□ □□□ □□□□ □□ □□□□□ □□□□ □□□□□	□□□□□ 1-12, □□□□□ □□□ □□□□, □□□□□ □□□	□□□□□ □□□□□□□□ □□ □□□ □□□ □□□□ □□□□□ □□□ □□□□□□□ □□□ □□□□ □□ □□□□□□ □□□□□□□□ □□□□ □□, □□□ □□ □□ □□□□□ □□ □□□□ □□ □□□□□ '□□ □□□ □□□ □□ □□□□ □□□□ □□ □□□□□ □□□ □□□□□□ □□□ □□□□, □□□-□□□□□□□ □□□□□□□□□□□□□ (□□□□□ □□□□□ □□□□) □□□□ □□□ □□□□ □□□□□ □□□ □□□□□ □□□□ □□ □□□□ □□□ □□ MAT (□□□□□□□□□□-□□□□□□□□ □□□□□□□□□□) □□□ □□□ □□ □□□□ □□ □□□□ □□□
□□□□□□□	BDNF □□ □□□□ □□□□□; □□□□□ □□□□□; □□□□□□□□□ □□□ □□□□□□□□□ □□□□; □□□□□□□□ □□□□□□□ □□ □□□□□ — □□ □□ □□□□□□ □□ □□ □□□□□□ □□□□□ □□ □□□□□ □□□ □□□□ □□ □□□ □□□□□ □□□□ □□□□□ □□□□ □□□ □□□ □□□□ □□□ □□□□□□□□ □□□ □□ □□□□□□ □□ □□□□□□□□ □□□	□□□□□ 2 □□□ □□□□□ □□□□□□□	□□□□□□ □□□□□□□□ □□ □□□□□ □□□ □□□□□ □□ □□□ □□□□□, □□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□ □□, □□□□ □□□□□□□ □□□□□ □□ □□□□ □□—□□□ □□□□ □□□□□ □□□ □□□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□ Semax, □□ □□ BDNF □□□□□ □□□□□□□□□□ □□□□□□ □□□□□□ □□□□□ □□, □□□□□ □□□□□□□□ □□□ □□□ □□□ □□□□ □□□ □□ □□□□ □□□ □□ □□□ □□□ '□□ □□□□□□□□ □□□□□□ □□ □□ □□□□

			[illegible] [illegible] [illegible]

[illegible] 5 — [illegible] [illegible] - [illegible] [illegible]

[illegible] — [illegible] [illegible] [illegible]

		[illegible]
[illegible] / [illegible] / [illegible]	[illegible] (supervised abstinence) [illegible] —[illegible], [illegible], [illegible] (detox)[illegible] ([illegible]), [illegible], [illegible]	[illegible]: [illegible] Naloxone [illegible], MAT ([illegible]) [illegible], [illegible], [illegible] 72 [illegible], MAT [illegible]
[illegible] - [illegible], [illegible], [illegible]	[illegible]: [illegible], [illegible], [illegible], [illegible]—[illegible], [illegible]:[illegible]	[illegible] 05 ([illegible]) [illegible], [illegible]-[illegible], [illegible] ([illegible]) [illegible], [illegible]—[illegible]
[illegible] — [illegible], [illegible], [illegible], [illegible]	[illegible] MOR [illegible] - [illegible]-[illegible]: [illegible]	[illegible]-[illegible] ([illegible] 6) [illegible]-[illegible] MOR [illegible] findahelpline.com [illegible] - [illegible]

[illegible] - 5 [illegible].

10. [illegible]—[illegible], [illegible], MAT [illegible] findahelpline.com [illegible] priority [illegible], [illegible]

11. 4-7-8 [illegible] [illegible] [illegible]—[illegible] [illegible] [illegible] [

□□□□ 6 — □□□□□□ □□□□□□□□ □□□□□ □□ □□□□□□.

□□ □□□□□□□□□□ — □□□□□□□□□□ □□□□ □□-28, □□□□□□□ □□□□□□ '□□ □□□□□ □□□ □□□ □□□ □□□ □□□□ □□□□, □□□ □□□□ □□□□ □□□ □□□□□□ □□□ □□ □□□ □□ □□ □□ □□□□□ □□□□ □□ □□□□ □□□

□□□□□□□□ □□□ □□□ □□□□ □□□□□□ □□□□ □□: □□□ □□□□□ □□□ □□□ □□□ □□□□ □□ □□□□ □□□□□□ □□□□□ □□ □□ □□□□□ □□□ □□□□□□ □□□□□ □□□ □□□□□□□ □□ □□□□□, □□□□□ □□□ □□ □□□□□, □□□ □□□□ □□□□□ □□ □□□□□, □□□ □□□ □□□□□□ □□□□□□ □□□ □□□□ □□□□ □□□ □□□□□□ □□□□□□ □□□□□ □□, □□ □□□□□□ □□□□ □□ □□□ □□ □□□□□ □□□ □□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□□□ □□ □□ □□□ - □□□□□ □□□□□ □□□, □□□ □□□□□ □□□, □□□ □□□□□□□ □□□ - □□ □□□□ □□ □□□□□□□□ □□□ □□□□□□ □□□ □□□ □□□□□□ □□ □□□□ □□□

□□□□□ □□ □□□□□ □□□□□□□□□ □□□□ □□□□□□□□□ □□□□ □□□□ □□□ □□: "□□□□□□ □□□□□ □□□ □□□□... □□□□□-□□□□□□□□□□, □□□, □□□□□□□... □□□□ □□□□□ □□□□ □□ - □□ □□□□ □□ □□□□□□□□ □□□ □□□□□□ □□□□ □□□" □□□□□□ □□ □□□□□□ □□□□ □□ □□□□□□□ □□□□□ □□□□ □□□ □□ □□ □□□□□ □□□ □□□ □□□□□□ □□ □□ □□□□□ □□□□□□□□ □□□□ □□□

□□□□□□ □□□□□□□□ □□□□□□□□□□

□□□□□□□□ □□□□	**MOR** □□□□□□□□□□ □□ □□□□□□□	□□□□□ □□□□ □□□□ □□□	□□□□□ □□□ □□□□, □□ □□□ □□ □□□□ □□□□□□□ □□□□□□ □□□□ □□ □□□□□ □□□□ □□□□ □□ □□□□□ □□□□ □□□□□ □□□ □□, □□□ □□□□□ □□□□ □□□□□ □□□ □□□□□□□□□ □□□ □□□ □□□□
□□□□ □□□ □□□□□□ □□□□ — □□ □□□□□□□□ □□□ □□□□ □□□ □□ □□□□ □□□□□ □□□	□□□— □□□□□□□□ □□ □□ □□□ □□□ □□□□□□ □□□□□ □□□- □□□□□□ □□□□ □□□ □□□□□ □□□	□□□□□, □□□□□, □□□□□ □□□□□□, □□□ □□□□□ - 45+ □□□□, □□□□□□□□□□ □□□ □□□□ □□□□□□ □□□ □□□□ □□□□, □□ □□□□ □□□□ □□□□ □□□□□□ □□□ □□□□□□□	□□□□□□ □□□□□□□□ □□□ □□□□□ □□□ '□□ □□□□□□ □□□□ □□, □□ □□ MOR □□□□□□□□□□ □□□ □□□□□ □□□□ □□ — □□□ □□ □□□□□□□ □□ □□□□□□□ □□□ □□□□□□□ □□□□□□pt □□ □□□□ □□□ □□ □□□ □□□-□□□□ □□□□ □□□ □□□□□□ □□□ □□□□ □□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□ □□□□ □□, □□ □□ □□□ □□□□□ □□□□ □□□□□ □□□□□ □□□ □□ □□□ □□□□□, □□ □□□□- □□□□□□ □□□□□□□□□□□ □□□□□ (BDNF) □□□□ □□□□ □□, □□ □□□□□□ □□□□□□ □□□ □□□ □□□ □□□□ □□□ □□□□ □□, □□□ □□ □□ □□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□ □□ □□□□□ □□□ □□□□□□ □□ □□□□ □□□□ □□ □□□□□□□□ □□□ □□□□ □□□□ □□□ □□□□□ □□□ □□ □□□□ □□□□□□ □□□ □□□□□ 1 □□□□□ □□□, □□□□□ □□ □□□□□□ □□ □□□□□ □□□□ □□□□ □□□□ □□□□ □□□□□

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]

			□□□□□□□□□, □□□□□□□□□ □□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□□ □□□□□ □□ (□□□□□□□□□ □□□□ '□□ □□□□□ □□□□□□ □□□□ □□□□□□□□□□ □□□□ □□□□□□□□□ □□ □□□□□□ □□□□□□)□
□□□□□ - □□□□ □□□□ '□□ □□□□□□□ □□□□□□ □□ □□□□□□□□ □□□□ □□□□□ □□ □□□□□□ □□□□	□□□□ □□□□ □□□□□□□ - □□□□ □□□□□□□ □□ □□□□□ □□□□ □□□□□□□□□□□	□□□□□ □□□□□□□ □□□□□□□, □□□□□□ □□□□□□□□□, □□□□□ □□□□□□ □□□□□ □□□□□□□□□□□□, □□□□□□□□-□□□□□□ □□□□□□□□□□□□, □□□□□□□□□ □□□□□□□□□□□ □□ □□□□□□□ □□□□□ □□ □□□□□ □□□□□□□ □□□□ Naloxone □□ □□□□□□ □□□□	□□□□□□ □□□□□□□ □□□□□□□□ □□□□ □□ □□ □□—□□□□□□ □□□□□ □□ □□□□ □□□□□□□ □□ □□□□□□□□□ □□□□□□□ (□□□□□□□□) □□□□□□□ □□□□□□ □□, □□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□ □□, □□□□□□ □□□□□ □□□□□ □□□□□□□ □□ □□□□□□ □□□□□ □□, □□□□ □□□□□□ □□□□□ □□□□□□ □□— □□ □□□□ □□□□□□□□ □□□□□ □□□□□□ □□ □□ □□□□□ □□ □□□□□□□□ □□□□□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□, □□ □□□□□ □□□□ □□□□□□□□ □□□□ □□ □□□□□□□ □□ □□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□ □□□□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□ □□□□
□□□□□□□□□□ □□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□	□□□□ □□□□ □□□□ □□□□□, □□□□ □□□□□□□ □□□□□□ - □□□□□□□□□, □□□□, □□□□ □□□□□□ □□□□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□□ MOR (□□□□ □□□□□ □□ □□□□□□□ □□□□□□□□□□) □□□□ □□□□□□ □□□□□□	□□□□ □□ □□□□□□□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□□ □□□□□□ □□ □□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□ □□—□□□□□ □□□□□□ □□□□□□□□□, □□□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□ □□□□	□□ □□□□□□□□ □□ □□□□□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□□□ '□□ □□□□□ □□□□□□ □□, □□□□ □□□□□ □□□□□□□□ □□□□□□ □□: □□□□ □□□□□□□ □□□□□□□ □□□□ □□ □□□□□□□□ □□□□□ □□□□ □□□□□ □□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□ □□ — □□ □□□□□□ □□ □□ □□□□□ □□□□ □□, □□ □□□□ □□□□□□□□□□ □□, □□□□ □□□□□ □□□□□ □□□□ □□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□ □□□□□□□ □□ □□□□ □□□□ □□ □□□□□, □□□□□ □□□□□□□□ □□□□□□ □□□□□□ □□□□ □□□□ □□□□□□□□ □□□□

□□□□ 7 — □□□□□□ □□□□ □□□ □□□□□: □□□□□□ □□□□□□□□□ □□□.

□□□□	□□□□□□□□□□	□□□□ □□□□□	□□□□□□□□ □□□□□ □□□□□
□□□□□ □□□□□□□ (□□□ 0)	□□ □□□□ □□ □□□ 0 — □□□□□□□□, 112, □□□□ □□□□□.	□□□□□□□□ □□□ □□□□; □□□□□□□ □□□□ □□ □□□□□□; □□□□□□□□□ □□□□ □□□□□□□; □□□□□□□□ □□□□ □□□□□□□	□□□□ □□ □□□□□ □□□ □□ □□□□□□□ □□□ □□□□□□, □□□□□ □□□□ □□ □□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□□ □□□ Naloxone □□□□□□ □□□ □□□□ □□□□□□□ □□□□□ □□□□ □□ □□□□□ □□□□ □□□ □□□□ □□□□□ □□□ □□□ □□□□ □□ □□□□ □□□□ □□: □□□□□□ □□□ □□□ □□ □□□□ □□□□□□□ □□□□ □□□□□□, □□□ □□ □□□□□ □□□□ □□□□□ □□ □□□, □□□□ Naloxone □□□□, □□□ 112 □□□ □□□□□ □□□□ □□□□□
MAT □□□□□□□□ (□□□ 0-7)	MAT □□□□□□□□□□□□ □ □□□ OTP — □□ □□□□ □□ □□□ 3□	□□□□□□□□□□□□□ □□□ □□□□□□□ □□□□□□□; □□□□□□ □□□□□□□; □□□□□□□-□□□□□□□ □□□□□□□ □□□□.	MAT (□□□) □□□□□ □□□□ □□ □□□□□□ □□□□ □□ □□□ □□□□□ □□□□ □□ □□□ □□□□□□ □□□ □□□ □□□□□□ □□□ □□□□ □□ □□ □□□□□ □□□□ □□□□ □□□□□□ □□□ □□□□□□ 4 □□□□ □□□□□ □□□ □□□□□□□□ □□□□, MAT □□ □□□ □□ □□□□□ □□□□□ □□ - □□ □□□□ □□, □□□ □□□□□ □□□□ MAT □□□ □□□□ □□□□□ □□ □□□□ □□: □□□ □□□□ □□□□□ □□□ □□ □□□□ □□□ □□□ □□□ □□□□ □□□ □□□□ □□□□□□ □□□□□ '□□ □□□□ □□□□ □□□ □□ □□□□ □□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□
□□□□□□□□□□ □□□□ (□□□ 1-14)	□□□□□□□□□□ 07, □□□□□□□□□□ 09, □□□□□□□□□□ 17, □□□□□□□□□□ 18	DLPA, NAC, 5-MTHF, □□□□□□□□□□, □□□□□□-3, DLPA, □□□□ □□□□, □□□□□, □□□□□□□□□.	DLPA □□□ NAC □□□□□ □□□□ □□□□□□□□□□ □□□□□ □□□□ 5-MTHF □□□□□ □□□□ □□ □□□□ □□□□□: □□□□□□□□ □□□□□ □□□ □□□□□ (DLPA), □□□□□□□□ □□ □□□□ (NAC), □□□ □□□□□□□□ □□ □□□□□□ (5-MTHF)□ □□□□□ □□□□ □□□□□□ □□□□ □□□□ □□ □□□□ □□, □□□□□ □□ □□ □□□ 10-□□□□ □□ □□□□ □□ □□□□□ □□□□ □□□ □□□□□□□□ □□ □□□□□□ □□□□□ □□□□□ □□□□□ □□□
□□□□□□□ □□□□□□□ (□□□□□ 1)	□□□□□, □□□□□□ □□□□□□, □□□□□ □□ □□□□□□	HCV □□□□□□□ □□□ □□□□; HIV □□□□□□□; □□□□ □□ □□□□□ □□□□□□ □□ □□□ □□ □□□□; □□□□□□□ □□ □□□□□□□; □□□ □□□□□□□ □□□□□□	HCV □□□□ □□□□□ 1 □□□□ □□□□□ □□□□ □□□□□□ □□ □□□□ □□□□□ □□□□□ □□ □□□□□□ □□ □□□□□ □□—□□□□□□□□ □□□□□ HCV □□ □□□□ □□□ □□□ □□□□□ □□□□□ □□□□□□ □□□ HIV: ART □□□□□ □□□□□ □□□ □□□ □□□□ HIV □□□□□□□ □□□ □□□□ □□□□□□ □□□□ □□□□ □□□□□□□ □□□—MAT (□□□□□□□□) □□ CYP3A4 □□□ □□□□□ □□□□□ □□□□□□ □□□ '□□

			□□□□□□□□□□□□ □□□
□□□□□□□□□ □□□□□□□□ (□□□□□□ 1-4)	□□□□□ □□□□: □□ □□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□□□□ □□ □□□□ □□□□□□ □□□□□ □□ □□□□□□□ □□ □□□□□□□ □□□□□ □□□□□ □□□□□ □□□□□□□ □□□□□□□□□ □□□□□ □□□□ □□, □□□□□□ □□□□□ □□□□ □□□□□ □□ □□□□□□□ □□ □□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□□□□ □□ □□□□□□□ □□□□ □□□□□ □□□□□□□□□ □□□□□ □□ □□□□□ □□□□□ □□□□ □□□□□□ □□, □□□□ □□□□□□ □□□□□ □□□□□ □□□□□□ □□□□ □□□□□□□□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□□□ □□□□□, □□□□□□□ □□□□□□□ '□□ □□□□□ □□□□: * OPRM1 * CYP2D6 * CYP3A4 * COMT * MTHFR	MAT □□□□□ □□ □□□□□□□□□□□ (OPRM1); □□□□□□ □□□□□□□□□□□□ □□□□□□□□ (CYP2D6, CYP3A4); □□□□ □□□□□□□□ (COMT); □□□□□□□□□□ □□□□ (MTHFR)	OPRM1 □□□□ □□ □□□□ □□□□□□□□□□□□□ □□ □□□□□□□□□ □□□□ □□□□□□□□□ □□□□□ □□ — □□ □□□□□□□□□□□□□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□□□□□□□□ (□□□□□□□□□□) '□□ □□□□□□ □□□□□ □□ □□□□□ □□, □□□□ OPRM1 □□□□□ □□□□□ □□ □□□□ □□ □□ □□□□ □□□□□ □□□□□□□□□□□ □□□□□□□ □□□□□ □□□□ CYP3A4 □□□□ CYP2D6 □□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□□□ □□ □□□□□□ □□□□□□□□□ □□ □□□□□ □□□□□ □□□□□□□□□ □□□□□□ □□□□
□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□ (□□□□□□ 1-12)	□□□□□□□□□□□ 03 (□□□□□□), □□□□□□□□□□□ 04, □□□□□□□□□□□ 08, □□□□□□□□□□□	□□□□□□□□ □□□□□□□□□ □□□□□; □□□□□ □□□□□□□□; □□□□□□; □□□□□ □□□□□ □□□□□□; □□□□□□; □□□□□□	□□□□□□□□□ □□ □□□□□□ □□□□ □□□□□□□, □□□□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□ □□, □□□□□ □□□□□ □□□□□ □□ □□□□□ □□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□□□□ □□□□ □□□□□□□□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□ □□ □□□□□□□ □□□□□□ □□□□ □□ □□□□□ □□□□□□

	22; □□□ 6		□□□□ □□□□□□ □□□ □□ □□□□□ □□ □□□□□□□ □□□ □□□□ □□□□□□, □□□ □□□ □□□ □□□□ □□□□□□□□ □□□□□ □□□□□ □□ □□□□ □□ □□□□ □□ □□□ □□□ □□□□□ □□□ □□□□ □□□
□□□ □□□□□□□ □□□□ (□□□□□ 1-12+)□	□□□ □□□□□□□ □□□□□; MAT (□□□□□□□□□□-□□□□□□□ □□□□□□□□□) □□□□□□□□□□□ ; □□□□□□□ □□□□□□□□□	□□□□□ □□□ □□□□□ □□□□ □□□□ □□ □□□ □□ □□□□□□□; □□□□□□□ □□□□□□; □□□ □□ MAT.	□□□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□□□ □□□□ □□□□□□□ □□□ □□□□□, □□□□□□ □□□ □□□□□ □□: □□□ □□□□□□□ □□ □□□□□ □□□□□ □□ □□□□□ □□ □□□-□□□ □□□□□ □□ □□□ □□□□□□ □□□□ □□ □□□□□ □□□□□ □□□ □□ □□□□□ □□□□□ □□□□□ □□□ □□□□□□□□□□□□□ □□ □□□□□□□ □□□□ □□□□ □□□□ □□□□□ □□□ □□□□□□□ □□□□ □□— □□ □□□□ □□□□ MAT (□□□□□□□□□□-□□□□□□ □□□□□□□□□□) □□□□□□□□□□□□□ □□□ □□□□□□ □□ □□□ □□□□
□□□□ □□□ □□□□ □□□□□ (□□□□□ 6+)	□□□□□□□□□□ 20, □□□□□□□□□□ 21, □□-28; □□□□ □□□□□□ □□□□□□□	□□□□□ □□□□□□ □□□□□□□□ □□□ □□ □□; □□□ □□□□ □□□ □□□□□□ □□□□ □□□□□, □□ □□□□ □□□□□□□□ □□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□	□□□□□□□□ □□ □□□□□ □□□ □□□□□ □□□□□□□□□ □□□□ □□□ □□□□□ □□ □□□□□□□ □□□□□□, "□□□□ □□□□□" □□ □□ □□□ □□□□□□ □□□□ □□□ □□ □□□□□□ □□ □□□□□□□ □□□ □□□□ □□□□□ □□□□□□ '□□ □□ □□□□□ □□, □□ □□□□ □□ □□ □□□ □□□□□ □□□□ □□□□ □□□□ □□□ □□□□□ □□ □□□ □□□□□□ □□ "□□□ □□ □□□ □□□□□ '□□ □□□□ □□□," □□ □□ □□□□ □□□□ □□ □□ □□□□□□ □□□□ □□ - □□ □□□□□□ □□□□□□ □□ □□ □□□ □□□□□□ □□□□ □□□□ □□ □□□ □□□□□□□□□ □□□ □□ □□□□ □□□

[illegible] 8 — [illegible]: [illegible], [illegible], [illegible]

[illegible], [illegible]: [illegible] ([illegible], [illegible], [illegible] 13 [illegible] 400,000 [illegible]), [illegible], [illegible], [illegible], [illegible], [illegible]

8.1 — [illegible]

- DEA X-waiver [illegible] (2023): [illegible] DEA-[illegible], [illegible], [illegible] - [illegible]
- [illegible]: [illegible] 47 [illegible] - [illegible] 112 '[illegible], [illegible] '[illegible] 112 '[illegible]
- [illegible]: [illegible], [illegible]-[illegible], [illegible]-[illegible] (MAT), [illegible]-[illegible] (MAT) [illegible]-[illegible]-[illegible]
- [illegible]: [illegible] MAT ([illegible]) [illegible] MAT [illegible] ACA [illegible] 2023 [illegible] '[illegible]: [illegible], [illegible], [illegible]

8.2 — [illegible]

- SAMHSA (Substance Abuse and Mental Health Services Administration): findtreatment.gov for treatment locators; 1-800-662-4357 for navigation assistance; SAMHSA's TIP 63 (medications for opioid use disorder) is the federal clinical guideline

- [illegible] [illegible] [illegible] [illegible] [illegible] (ASAM): asam.org; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: naabt.org; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- NEXT Distro (nextdistro.org): [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] Naloxone [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- SMART Recovery: smartrecovery.org; [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible], 12-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible]: na.org; 12-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible]: 1-844-289-0879 (24/7)

[redacted]

[redacted] — [redacted] — [redacted]

2022 [redacted], [redacted] [redacted] 110,000 [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] 110,000 [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] 1995 [redacted] AIDS [redacted] [redacted] [redacted] HIV [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted], [redacted] [redacted], [redacted] [redacted], [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted] [redacted]

— — —

Naloxone: any US pharmacy without prescription | Treatment locator: findtreatment.gov | Crisis: 988 | SAMHSA: 1-800-662-4357

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

Crisis: call or text 988 | Emergency: 911 | SAMHSA: 1-800-662-4357 | National Drug Helpline: 1-844-289-0879

⚠ [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]